en · de · es
aod-9604-notes.peptides1004.com › Topic › Handling, Analysis, And Quality Control — Evidence Review

Handling, Analysis, And Quality Control — Evidence Review

By Editorial Desk · published 2026-01-31 · last reviewed 2026-03-19 · Topic

Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form; visual inspection
SolubilitySoluble in water and aqueous buffersDepends on pH, purity, and counterion
Typical storage-20 °C or below, desiccatedProtect from light; avoid repeated freeze-thaw after reconstitution
Common analytical methodReversed-phase HPLC and mass spectrometryPurity by HPLC; identity and mass by LC-MS or MALDI-TOF
Common synonymshGH fragment 176–191; AOD-9604Names vary in research and product labeling

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Related pages on this site

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Background and Molecular Identity

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Background from the literature

A group at the Nobel Institute for Physics in Stockholm independently discovered the element, producing an isotope later confirmed to be 250Fm (t1/2 = 30 min) by bombarding a 238U target with 16O ions, and published their work in May 1954. Nevertheless, the priority of the Berkeley team was generally recognized, and with it the prerogative to name the new element in honour of Enrico Fermi, the developer of the first artificial self-sustained nuclear reactor. Fermi was still alive when the name was proposed, but had died by the time it became official.

females age 12 to 21 may have iron deficiency (27 June), researchers show how bird flu could mutate to overcome a human antiviral protein to start another pandemic (28 June), shortages of medications – including some against cancer – are reported across countries, articles in science outlets like Nature suggest contemporary viral concerns about hypothetical existential risk of AI "plays into the tech companies' agenda" – partly in the form of 'criti-hype' – and that this "hinders effective regulation of the societal harms AI is causing right now" and in the near-future. Promising results of therapeutic candidates are reported: first phase 3 trialed chikungunya vaccine (VLA1553) (12 June), mice-tested inoculation against a potential infectious contributor to endometriosis (14 June), new evidence regarding still-unclear vaginal seeding interventions (15 June), phase 2 trialed orforglipron against obesity (23 June), mice-tested gene-therapy against hearing loss (28 June).

vitamin D – acute respiratory tract infections iron – maternal iron deficiency anemia and adverse effects on the fetus multiple supplements – no evidence of benefit to lower risk of death, cardiovascular diseases or cancer magnesium supplementation – in reducing all-cause and cancer mortality, as well as improving glucose parameters in people with diabetes and insulin-sensitivity parameters in those at high risk of diabetes. folate alone or with B vitamins – stroke A 2017 academic review indicated a rising incidence of liver injury from use of herbal and dietary supplements, particularly those with steroids, green tea extract, or multiple ingredients.

Sources: en.wikipedia.org

Reference notes

=== Two-stroke engines === A rotary valve in the form of a flat disc, also known as a disc valve, is used in two-stroke motorcycle engines, where the arrangement helps to prevent reverse flow back into the intake port during the compression stroke. Austrian engine manufacturer Rotax used rotary intake valves in their now out-of-production 64 hp (48 kW) Rotax 532 two-stroke engine design and continues to use rotary intake valves in the 532's successor, the current-production 64 hp (48 kW) Rotax 582. Wifredo Ricart, a Spanish engineer who worked at Alfa Romeo and then in Pegaso, who had applied for the 'Desmodromic' valve drive system in 1924, patent FR590149; patented, ES166367, 1944, a Rotary Valve for 2-Strokes; also an Itala type of Valve, patent ES0117737. Lotus tried something similar, SAE technical paper 920779.

Inhibition of radical SAM enzyme MqnE in menaquinone biosynthesis is reported to be an effective antibacterial strategy against H. pylori. Radical SAM enzyme BlsE has been discovered to be a central enzyme in blasticidin S biosynthetic pathway. Blasticidin S produced by Streptomyces griseochromogenes exhibits strong inhibitory activity against rice blast caused by Pyricularia oryzae Cavara. This compound specifically inhibits protein synthesis in both prokaryotes and eukaryotes through inhibition of peptide bond formation in the ribosome machinery. A new fungal radical SAM enzyme has also been reported to facilitate the biocatalytic routes for synthesis of 3'-deoxy nucleotides/nucleosides. 3'deoxynucleotides are a class of drugs that interfere with the metabolism of nucleotides, and their incorporation into DNA or RNA terminates cell division and replication. This activity explains why this compound is an essential group of antiviral, antibacterial or anticancer drug.

=== Transition and swearing-in ceremony === Melo named Porto Alegre councilman and former mayor of Santa Maria, Cezar Schirmer, as his transition coordinator for the transition between the Marchezan government and his. In his inaugural speech on 1 January 2021, Melo affirmed that was necessary to "raise the optimism" for the city, as the city, due to the COVID-19 pandemic, had been going through rough times economically and socially.

Sources: en.wikipedia.org

Frequently asked questions

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

What methods confirm AOD9604 identity?

Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.

Is AOD9604 the same as human growth hormone?

No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Network